<DOC>
	<DOCNO>NCT02877134</DOCNO>
	<brief_summary>The purpose study assess safety efficacy JNJ-64304500 participant moderately severely active Crohn 's disease .</brief_summary>
	<brief_title>Safety Efficacy Study JNJ-64304500 Participants With Moderately Severely Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Have Crohn 's disease fistulizing Crohn 's disease least 3 month ' duration , colitis , ileitis , ileocolitis , confirm time past radiography , histology , and/or endoscopy A woman childbearing potential must negative highly sensitive serum ( betahuman chorionic gonadotropin [ bhCG ] ) pregnancy test result screen negative urine pregnancy test result Week 0 Adhere follow requirement concomitant medication treatment Crohn 's disease , permit provide dos meeting requirement stable , discontinue , least 3 week baseline ( Week 0 ) , unless otherwise specify : ) Oral 5aminosalicylic acid ( 5ASA ) compound , b ) Oral corticosteroid prednisoneequivalent dose 40 milligram per day ( mg/day ) , 9 mg/day budesonide , 5 mg/day beclomethasone dipropionate , c ) Antibiotics use primary treatment Crohn 's disease , ) Conventional immunomodulators ( , azathioprine ( AZA ) , 6mercaptopurine ( 6MP ) , Methotrexate ( MTX ) ) : participant must take least 12 week stable dose least 4 week baseline A participant extensive colitis great equal ( &gt; = ) 8 year , disease limit left side colon &gt; = 12 year , must either colonoscopy ass presence dysplasia within 1 year first administration study agent colonoscopy assess presence malignancy screen visit , evidence malignancy Have active Crohn 's disease , define baseline Crohn 's Disease Activity Index ( CDAI ) score &gt; = 220 &lt; = 450 Participants receive intravenous ( IV ) corticosteroid less ( &lt; ) 3 week receive tumor necrosis factoralpha ( TNFalpha ) antagonist biologic agent ( example , monoclonal antibody [ mAb ] therapy ) agent intend suppress eliminate tumor necrosis factoralpha ( TNFalpha ) &lt; 8 week receive Vedolizumab &lt; 16 week first administration study drug Woman pregnant planning pregnancy man plan father enrol study within 16 week last administration study agent Participants certain complication Crohn 's disease would make hard ass response study drug Participants history ongoing chronic recurrent infectious disease Has previously receive biologic agent target interleukin ( IL ) 12 IL23 , include limited ustekinumab briakinumab ( ABT874 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>